Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study. 2018

Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
Department of Nephrology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China, 325000.

The renal prognosis and treatment of primary IgA nephropathy (IgAN) patients with segmental glomerular necrosis (SGN) remain controversial. Patients with primary IgAN confirmed by renal biopsy were enrolled. Patients with SGN on renal biopsy were selected as the necrosis group, and a propensity score matching method was used to match a control group according to age, gender, weight, height and follow-up time. A total of 825 IgAN patients were enrolled in the present study. Seventy-three (8.8%) patients with SGN were selected as the necrosis group, and 292 patients without SGN were matched as the control group. Compared to the control group, a significantly increased serum fibrinogen level (3.97 g/L vs 3.54 g/L, P=.002) and proportion of patients with macroscopic hematuria (35.6% vs 14.7%, P<.001) was observed in the necrosis group. According to the new IgA pathological classification system, crescent formation was more pronounced in the necrosis group (P=.001). The average estimated glomerular filtration rate was obviously higher in the necrosis group and decreased more slowly during follow-up. However, the time-averaged urine protein-to-creatinine ratio remained low in the necrotic group, whereas it gradually increased in the control group. SGN suggests an active renal inflammatory state, but it was not an independent risk factor for a poor renal outcome in patients treated with immunosuppressive therapy. Furthermore, patients with SGN had a more stable renal function and low urinary protein excretion during follow-up, which may be attributable to aggressive immunotherapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007673 Kidney Cortex Necrosis Death of cells in the KIDNEY CORTEX, a common final result of various renal injuries including HYPOXIA; ISCHEMIA; and drug toxicity. Renal Cortical Necrosis,Glomerular Necrosis,Renal Tubule Necrosis,Necrosis, Glomerular,Necrosis, Kidney Cortex,Necrosis, Renal Cortical,Necrosis, Renal Tubule
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
January 2016, American journal of nephrology,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
December 1993, Acta pathologica japonica,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
November 2020, Renal failure,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
September 2005, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
July 2016, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
December 2016, Clinical and experimental nephrology,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
August 2017, Transplantation direct,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
December 2017, Nephrology (Carlton, Vic.),
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
January 2008, Renal failure,
Min Pan, and Ji Zhang, and Xiaohan You, and Duo Li, and Yinqiu Lv, and Jianna Zhang, and Xiaokai Ding, and Zhanyuan Li, and Feifei Xu, and Chaosheng Chen
January 2021, PloS one,
Copied contents to your clipboard!